Sanofi's Sarclisa cuts death risk in mutiple myeloma
admin 12th May 2020 Uncategorised 0The Phase III IKEMA trial hit its primary endpoint More: Sanofi's Sarclisa cuts death risk in mutiple myeloma Source: News
read moreThe Phase III IKEMA trial hit its primary endpoint More: Sanofi's Sarclisa cuts death risk in mutiple myeloma Source: News
read moreThe research funded will help inform policy decisions during the novel coronavirus pandemic More: NIHR, UKRI call for new COVID-19 research proposals Source: News
read moreThe selective RET kinase inhibitor was cleared under the regulator’s accelerated approval process More: Lilly's Retevmo wins US nod for specific lung, thyroid cancers Source: News
read moreThe groups will explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicine products More: Cell and Gene Therapy Catapult links with Japan's CiRA Foundation Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals